ThermoGenesis (THMO) 10-Q 14 May 19 2019 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 10, 2019
Document Information [Line Items]
Entity Registrant Name	CESCA THERAPEUTICS INC.
Entity Central Index Key	0000811212
Trading Symbol	kool
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		23,649,147
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 2,237,000	$ 2,400,000
Accounts receivable, net of allowance for doubtful accounts of $426,000 ($419,000 at December 31, 2018)	1,994,000	1,509,000
Inventories, net of reserves of $344,000 ($258,000 at December 31, 2018)	4,309,000	4,493,000
Prepaid expenses and other current assets	313,000	224,000
Total current assets	8,853,000	8,626,000
Restricted cash	1,000,000	1,000,000
Equipment and leasehold improvements, net	2,443,000	2,562,000
Right-of-use operating lease assets, net	941,000
Goodwill	781,000	781,000
Intangible assets, net	1,561,000	1,591,000
Other assets	51,000	51,000
Total assets	15,630,000	14,611,000
Current liabilities:
Accounts payable	2,464,000	2,423,000
Accrued payroll and related expenses	470,000	703,000
Deferred revenue	764,000	485,000
Interest payable – related party	461,000	1,513,000
Other current liabilities	1,448,000	1,241,000
Total current liabilities	5,607,000	6,365,000
Convertible promissory note – related party, less debt discount of $6,953,000 ($6,026,000 at December 31, 2018)	1,760,000	1,174,000
Note payable	800,000
Derivative obligations	1,000	1,000
Long term operating lease obligations	854,000
Other non-current liabilities	329,000	340,000
Total liabilities	9,351,000	7,880,000
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none outstanding
Common stock, $0.001 par value; 350,000,000 shares authorized; 22,149,147 issued and outstanding (21,649,147 at December 31, 2018)	22,000	22,000
Paid in capital in excess of par	234,624,000	235,868,000
Accumulated deficit	(229,306,000)	(227,435,000)
Accumulated other comprehensive loss	(17,000)	(13,000)
Total Cesca Therapeutics Inc. stockholders’ equity	5,323,000	8,442,000
Noncontrolling interests	956,000	(1,711,000)
Total equity	6,279,000	6,731,000
Total liabilities and stockholders’ equity	$ 15,630,000	$ 14,611,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Accounts receivable, allowance for doubtful accounts	$ 426,000	$ 419,000
Inventories, reserves	344,000	258,000
Debt discount	$ 6,953,000	$ 6,026,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	350,000,000	350,000,000
Common stock, shares issued (in shares)	22,149,147	21,649,147
Common stock, shares outstanding (in shares)	22,149,147	21,649,147

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Net revenues	$ 2,962,000	$ 1,867,000
Cost of revenues	1,704,000	1,515,000
Gross profit	1,258,000	352,000
Expenses:
Sales and marketing	341,000	325,000
Research and development	563,000	1,041,000
General and administrative	1,260,000	2,242,000
Total operating expenses	2,164,000	3,608,000
Loss from operations	(906,000)	(3,256,000)
Fair value change of derivative instruments	0	259,000
Interest expense	(1,132,000)	(361,000)
Other expenses	(9,000)	(12,000)
Net loss	(2,047,000)	(3,370,000)
Loss attributable to noncontrolling interests	(176,000)	(410,000)
Net loss attributable to common stockholders	(1,871,000)	(2,960,000)
Net loss	(2,047,000)	(3,370,000)
Other comprehensive income:
Foreign currency translation adjustments	(4,000)	7,000
Comprehensive loss	(2,051,000)	(3,363,000)
Comprehensive loss attributable to noncontrolling interests	(176,000)	(410,000)
Comprehensive loss attributable to common stockholders	$ (1,875,000)	$ (2,953,000)
Per share data:
Basic and diluted net loss per common share (in dollars per share)	$ (0.08)	$ (0.27)
Weighted average common shares outstanding – basic and diluted (in shares)	24,614,147	10,899,225

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2017	10,872,428
Balance at Dec. 31, 2017	$ 11,000	$ 221,371,000	$ (187,640,000)	$ (43,000)	$ 33,699,000	$ (487,000)	$ 33,212,000
Stock-based compensation expense		137,000			137,000		137,000
Foreign currency translation				7,000	7,000		7,000
Net loss			(2,960,000)		(2,960,000)	(410,000)	(3,370,000)
Issuance of common stock and warrants in financing, net of offering costs (in shares)	609,636
Issuance of common stock and warrants in financing, net of offering costs		1,213,000			1,213,000		1,213,000
Cumulative-effect adjustment from adoption of ASC 606 | Accounting Standards Update 2014-09 [Member]			(79,000)		(79,000)		(79,000)
Balance (in shares) at Mar. 31, 2018	11,482,064
Balance at Mar. 31, 2018	$ 11,000	222,721,000	(190,679,000)	(36,000)	32,017,000	(897,000)	31,120,000
Balance (in shares) at Dec. 31, 2018	21,649,147
Balance at Dec. 31, 2018	$ 22,000	235,868,000	(227,435,000)	(13,000)	8,442,000	(1,711,000)	6,731,000
Stock-based compensation expense, net of stock surrenders (in shares)
Stock-based compensation expense		81,000			81,000		81,000
Exercise of pre-funded warrants (in shares)	500,000
Exercise of pre-funded warrants		5,000			5,000		5,000
Discount due to beneficial conversion features		1,513,000			1,513,000		1,513,000
Reorganization of subsidiary and related change in non-controlling interest		(2,843,000)			(2,843,000)	2,843,000
Foreign currency translation				(4,000)	(4,000)		(4,000)
Net loss			(1,871,000)		(1,871,000)	(176,000)	(2,047,000)
Balance (in shares) at Mar. 31, 2019	22,149,147
Balance at Mar. 31, 2019	$ 22,000	$ 234,624,000	$ (229,306,000)	$ (17,000)	$ 5,323,000	$ 956,000	$ 6,279,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net loss	$ (2,047,000)	$ (3,370,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	212,000	159,000
Stock based compensation expense	81,000	137,000
Amortization of debt discount	586,000
(Recovery of) reserve for excess and slow-moving inventories	86,000	(29,000)
Change in fair value of derivative obligation	0	(259,000)
Net change in operating assets and liabilities:
Accounts receivable	(485,000)	896,000
Inventories	99,000	(224,000)
Prepaid expenses and other assets	(90,000)	39,000
Accounts payable	38,000	69,000
Accrued payroll and related expenses	(232,000)	(92,000)
Deferred revenue	278,000	259,000
Other current liabilities	(932,000)	356,000
Other noncurrent liabilities	(37,000)	(4,000)
Net cash used in operating activities	(2,443,000)	(2,063,000)
Cash flows from investing activities:
Capital expenditures	(38,000)	(290,000)
Net cash used in investing activities:	(38,000)	(290,000)
Cash flows from financing activities:
Proceeds from long-term debt-related party	1,513,000	500,000
Proceeds from note payable	800,000
Proceeds from exercise of pre-funded warrants	5,000
Proceeds from issuance of common stock, net		1,213,000
Net cash provided by financing activities	2,318,000	1,713,000
Effects of foreign currency rate changes on cash and cash equivalents		(1,000)
Net decrease in cash, cash equivalents and restricted cash	(163,000)	(641,000)
Cash, cash equivalents and restricted cash at beginning of period	3,400,000	4,513,000
Cash, cash equivalents and restricted cash at end of period	3,237,000	3,872,000
Supplemental disclosures of cash flow information:
Cash paid for interest	1,514,000	3,000
Supplemental non-cash financing and investing information:
Recording of beneficial conversion feature on debt	1,513,000
Right-to-use asset acquired under operating lease	966,000
Transfer of equipment to inventories		$ 172,000

Note 1 - Description of Busines

Note 1 - Description of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Description of Business and Basis of Presentation Organization and Basis of Presentation Cesca Therapeutics Inc. (“Cesca Therapeutics,” “Cesca,” the “Company”), a Delaware corporation, develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company was founded in 1986 ® ® ® On January 1, 2019, July 2017 of ThermoGenesis named CARTXpress Bio, Inc. (“CARTXpress”) and the 20% 20% 80% 100% Cesca is an affiliate of the Boyalife Group, a China-based industry research alliance encompassing top research institutions for stem cell and regenerative medicine. The Company reacquired the non-controlling interest shares in ThermoGenesis with a deficit of $1,711,000 20% $1,100,000. $2,843,000 Liquidity and Going Concern The Company has a Revolving Credit Agreement (“Credit Agreement”) with Boyalife Asset Holding II, Inc. (Refer to Note 3 March 31, 2019, $8,713,000 $10,000,000 may may no At March 31, 2019, $2,237,000 $3,246,000. March 31, 2019 $229,306,000. one The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern; however, the above conditions raise substantial doubt about the Company’s ability to do so. The condensed consolidated financial statements do not may Principles of Consolidation The condensed consolidated financial statements include the accounts of Cesca and its wholly-owned subsidiaries, ThermoGenesis and TotipotentRX Cell Therapy, Pvt. Ltd and ThermoGenesis’ majority-owned subsidiary, CARTXpress Bio, Inc. All significant intercompany accounts and transactions have been eliminated upon consolidation. Interim Reporting The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) for interim financial information and with the instructions to Form 10 10 X. three March 31, 2019 not may December 31, 2019. 10 December 31, 2018.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Recently Adopted Accounting Standards In June 2018, 2018 07, “Compensation-Stock Compensation (Topic 718 718 January 1, 2019. not In February 2016, 2016 02 Leases January 1, 2019. The new standard requires lessees to recognize both the right-of-use assets and lease liabilities in the balance sheet for most leases, whereas under previous GAAP only finance lease liabilities (previously referred to as capital leases) were recognized in the balance sheet. In addition, the definition of a lease has been revised which may not The new standard provides a number of transition practical expedients, which the Company has elected, including: ● A “package of three” expedients that must be taken together and allow entities to ( 1 not 2 3 not ● An implementation expedient which allows the requirements of the standard in the period of adoption with no The impact of adoption did not January 1, 2019 one January 2019, five $966,000 Revenue Recognition Revenue is recognized based on the five 606: The following tables summarize the revenues of the Company’s reportable segments: Three Months Ended March 31, 2019 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 1,267,000 $ 55,000 $ 1,322,000 BioArchive 599,000 415,000 1,014,000 CAR-TXpress 307,000 -- 307,000 Manual Disposables 294,000 -- 294,000 Other -- -- $ 14,000 14,000 Total Device Segment 2,467,000 470,000 14,000 2,951,000 Clinical Development Segment: Manual Disposables 6,000 -- -- 6,000 Other 5,000 -- -- 5,000 Total Clinical Development 11,000 -- -- 11,000 Total $ 2,478,000 $ 470,000 $ 14,000 $ 2,962,000 Three Months Ended March 31, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 685,000 $ 65,000 $ 750,000 BioArchive 423,000 344,000 767,000 Manual Disposables 233,000 -- 233,000 CAR-TXpress 18,000 -- 18,000 Other 20,000 -- $ 17,000 37,000 Total Device Segment 1,379,000 409,000 17,000 1,805,000 Clinical Development Segment: Manual Disposables 22,000 -- -- 22,000 Bone Marrow -- 23,000 -- 23,000 Other -- 17,000 -- 17,000 Total Clinical Development 22,000 40,000 -- 62,000 Total $ 1,401,000 $ 449,000 $ 17,000 $ 1,867,000 Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not three March 31, 2019 $383,000. $764,000 $485,000 March 31, 2019 December 31, 2018, $300,000 $303,000 March 31, 2019 December 31, 2018, Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Remainder of 2019 2020 2021 2022 2023 and Beyond Total Service Revenue $ 1,047,000 $ 683,000 $ 413,000 $ 75,000 -- $ 2,218,000 Clinical Revenue 10,000 14,000 14,000 14,000 $ 198,000 250,000 Total $ 1,057,000 $ 697,000 $ 427,000 $ 89,000 $ 198,000 $ 2,468,000 Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues. Fair Value Measurements In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Level 2: Level 3: The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level 3 3 Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (CODM), or decision-making group, whose function is to allocate resources to and assess the performance of the operating segments. The Company has identified its chief executive officer as the CODM. In determining its reportable segments, the Company considered the markets and the products or services provided to those markets. The Company has two ● The Clinical Development Segment, is developing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets. ● The Device Segment, engages in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The device division is operated through the Company’s ThermoGenesis subsidiary. Net Loss per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus the pre-funded warrants. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration and have no 2,465,000 March 31, 2019 March 31: 2019 2018 Common stock equivalents of convertible promissory note and accrued interest 50,967,211 -- Vested Series A warrants 404,412 404,412 Unvested Series A warrants (1) 698,529 698,529 Warrants – other 15,578,847 4,030,600 Stock options 2,909,338 1,206,410 Restricted stock units -- 416 Total 70,558,337 6,340,367 ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021. Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not

Note 3 - Related Party Transact

Note 3 - Related Party Transactions	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	3 . Related Party Transactions Convertible Promissory Note and Revolving Credit Agreement In March 2017, $10,000,000 March 6, 2022 ( $8,713,000 $7,200,000 March 31, 2019 December 31, 2018, $1,287,000 may may no The Credit Agreement and the Convertible Promissory Note issued thereunder (the “Note”) provide that the principal and all accrued and unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% five The Maturity Date of the Note is subject to acceleration at the option of the Lender upon customary events of default, which include; a breach of the Loan documents, termination of operations, or bankruptcy. The Lender’s obligation to make advances under the Loan is subject to the Company’s representations and warranties in the Credit Agreement continuing to be true at all times and there being no The Credit Agreement and Note were amended in April 2018. $1.61 two 2018, $0.18. It was concluded that the conversion option did contain a beneficial conversion feature and as a result of the modifications to the conversion price, the Company recorded a debt discount in the amount of $7,200,000 $1,513,000 March 31, 2019. $586,000 three March 31, 2019. The Company recorded interest expense of $1,047,000 $360,000 three March 31, 2019 2018, $461,000 $1,513,000 March 31, 2019 December 31, 2018, Distributo r Agreement On August 21, 2017, ® ® ® ® ® The term of the agreement is for three two Revenues During the three March 31, 2019 2018, $266,000 $226,000, License Agreement On March 12, 2018, X ® Pursuant to the terms of the Agreement, ThermoGenesis has granted IncoCell an exclusive license to purchase and use, at a discounted purchase price, X ten may ninety 90 not three March 31, 2019 2018.

Note 4 - Note Payable

Note 4 - Note Payable	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	4. Note Payable On January 29, 2019, $800,000 six $0.001 $0.18 2 90% $0.05 The Note bears interest at the rate of twenty-four 24% eighteen 18 not fourteen may On the date that is six may 4.99% 9.99% The Note contains customary events of default, including the suspension or failure of the Company’s common stock to be traded on a trading platform, our failure to pay interest or principal when due, or if the Company files for bankruptcy or takes some other similar action for the benefit of creditors. In the event of any default under the Note, the holder may

Note 5 - Leases

Note 5 - Leases	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	5. Leases The Company determines if a contract contains a lease at inception. Our material operating lease consists of office space which has a remaining term of 5.2 Operating Leases Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not not The following summarizes the Company’s operating leases: March 31, 2019 Right-of-use operating lease assets, net $941,000 Current lease liability 94,000 Non-current lease liability 854,000 March 31, 2019 Weighted average remaining lease term 5.2 Discount rate 22% Maturities of lease liabilities by year for our operating leases are as follows: 2019 (remaining) $ 220,000 2020 301,000 2021 310,000 2022 319,000 2023 329,000 2024 138,000 Total lease payments $ 1,617,000 Less: imputed interest (669,000 ) Present value of operating lease liabilities $ 948,000 Statement of Cash Flows In January 2019, $966,000 first 2019. $71,000 first 2019 Operating Lease Costs Operating lease costs were $103,000 first 2019. 30 Finance Leases Finance leases are included in equipment and other current and non-current liabilities on the condensed consolidated balance sheet. The amortization and interest expense are included in general and administrative expense and interest expense, respectively on the statement of operations. These leases are not March 31, 2019.

Note 6 - Commitments and Contin

Note 6 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	6 . Commitments and Contingencies Financial Covenants Effective May 15, 2017, one not $2,000,000. March 31, 2019. Warranty The Company offers a warranty on all of its non-disposable products of one two The warranty liability is included in other current liabilities in the unaudited condensed consolidated balance sheets. The change in the warranty liability for the three March 31, 2019 Balance at December 31, 2018 $ 186,000 Warranties issued during the period 43,000 Settlements made during the period (107,000 ) Changes in liability for pre-existing warranties during the period (39,000 ) Balance at March 31, 2019 $ 83,000 Contingen cies and Restricted Cash In fiscal 2016, May 4, 2017, $1,000,000 $300,000 March 31, 2019) August 2016. October 2017, $1,000,000 June 26, 2018. September 24, 2018, No no March 31, 2019. In the normal course of operations, the Company may March 31, 2019, may not

Note 7 - Derivative Obligations

Note 7 - Derivative Obligations	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Derivatives and Fair Value [Text Block]	7 . Derivative Obligation s Series A Warrants Series A warrants to purchase 404,412 June 30, 2016. Series A March 31, 2019 December 31, 2018 Market price of common stock $0.29 $0.27 Expected volatility 96% 94% Contractual term (years) 1.9 2.2 Discount rate 2.28% 2.48% Dividend rate 0% 0% Exercise price $8.00 $8.00 Expected volatilities are based on the historical volatility of the Company’s common stock. Contractual term is based on remaining term of the respective warrants. The discount rate represents the yield on U.S. Treasury bonds with a maturity equal to the contractual term. The Company recorded a gain of $0 $259,000 three March 31, 2019 2018, The following table represents the Company’s fair value hierarchy for its financial liabilities measured at fair value on a recurring basis as of March 31, 2019 December 31, 2018: Derivative Obligation March 31, 2019 December 31, 2018 Balance $1,000 $1,000 Level 1 $- $- Level 2 $- $- Level 3 $1,000 $1,000 The following table reflects the change in fair value of the Company’s derivative liabilities for the three March 31, 2019: Amount Balance – December 31, 2018 $ 1,000 Change in fair value of derivative obligation -- Balance – March 31, 2019 $ 1,000

Note 8 - Stockholders' Equity

Note 8 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	8 . Stockholders ’ Equity Common Stock On March 28, 2018, 609,636 $2.27 $171,000, $1,213,000. 304,818 $2.68 six 5.5 Stock Based Compensation The Company recorded stock-based compensation of $81,000 $137,000 three March 31, 2019 2018, The following is a summary of option activity for the Company’s stock option plans: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2018 3,023,639 $ 1.40 Forfeited (114,301 ) $ 1.11 Outstanding at March 31, 2019 2,909,338 $ 1.41 9 -- Vested and expected to vest at March 31, 2019 1,911,105 $ 1.73 8.8 -- Exercisable at March 31, 2019 876,955 $ 2.79 7.9 -- The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock. There were no three March 31, 2019. Warrants A summary of warrant activity for the three March 31, 2019 Number of Shares Weighted-Average Exercise Price Per Share Balance at December 31, 2018 17,265,208 $ 2.99 Warrants expired (83,420 ) $ 56.20 Warrants exercised (500,000 ) $ 0.01 Outstanding at March 31, 2019 16,681,788 $ 2.81 Exercisable at March 31, 2019 15,983,259 $ 2.58

Note 9 - Segment Reporting

Note 9 - Segment Reporting	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	9 . Segment Reporting The Company has two The Clinical Development Segment is developing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets. The Device Segment is a pioneer and market leader in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The following table summarizes the operating results of the Company’s reportable segments: Three Months Ended March 31, 2019 Clinical Development Device Total Net revenues $ 11,000 $ 2,951,000 $ 2,962,000 Cost of revenues 43,000 1,661,000 1,704,000 Gross profit (32,000 ) 1,290,000 1,258,000 Operating expenses 471,000 1,693,000 2,164,000 Operating loss $ (503,000 ) $ (403,000 ) $ (906,000 ) Depreciation and amortization $ 95,000 $ 117,000 $ 212,000 Stock-based compensation expense $ 54,000 $ 27,000 $ 81,000 Goodwill -- $ 781,000 $ 781,000 Total assets $ 4,281,000 $ 11,349,000 $ 15,630,000 Three Months Ended March 31, 2018 Clinical Development Device Total Net revenues $ 62,000 $ 1,805,000 $ 1,867,000 Cost of revenues 71,000 1,444,000 1,515,000 Gross profit (9,000 ) 361,000 352,000 Operating expenses 1,179,000 2,429,000 3,608,000 Operating loss $ (1,188,000 ) $ (2,068,000 ) $ (3,256,000 ) Depreciation and amortization $ 68,000 $ 91,000 $ 159,000 Stock-based compensation expense $ 98,000 $ 39,000 $ 137,000 Goodwill $ 13,195,000 $ 781,000 $ 13,976,000 Total assets $ 38,941,000 $ 11,240,000 $ 50,181,000

Note 10 - Subsequent Events

Note 10 - Subsequent Events	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	10 . S ubsequent Event s On April 18, 2019, 4,444,444 $0.17 $755,555. Each pre-funded warrant is immediately exercisable for one $0.01 not 4.99% 9.99%, may not 61st may not 9.99%. The Offering closed on April 26, 2019. three sixty-five 365 In April 2019, 1,500,000 August 2018 $0.01 $15,000

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Standards In June 2018, 2018 07, “Compensation-Stock Compensation (Topic 718 718 January 1, 2019. not In February 2016, 2016 02 Leases January 1, 2019. The new standard requires lessees to recognize both the right-of-use assets and lease liabilities in the balance sheet for most leases, whereas under previous GAAP only finance lease liabilities (previously referred to as capital leases) were recognized in the balance sheet. In addition, the definition of a lease has been revised which may not The new standard provides a number of transition practical expedients, which the Company has elected, including: ● A “package of three” expedients that must be taken together and allow entities to ( 1 not 2 3 not ● An implementation expedient which allows the requirements of the standard in the period of adoption with no The impact of adoption did not January 1, 2019 one January 2019, five $966,000.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition Revenue is recognized based on the five 606: The following tables summarize the revenues of the Company’s reportable segments: Three Months Ended March 31, 2019 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 1,267,000 $ 55,000 $ 1,322,000 BioArchive 599,000 415,000 1,014,000 CAR-TXpress 307,000 -- 307,000 Manual Disposables 294,000 -- 294,000 Other -- -- $ 14,000 14,000 Total Device Segment 2,467,000 470,000 14,000 2,951,000 Clinical Development Segment: Manual Disposables 6,000 -- -- 6,000 Other 5,000 -- -- 5,000 Total Clinical Development 11,000 -- -- 11,000 Total $ 2,478,000 $ 470,000 $ 14,000 $ 2,962,000 Three Months Ended March 31, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 685,000 $ 65,000 $ 750,000 BioArchive 423,000 344,000 767,000 Manual Disposables 233,000 -- 233,000 CAR-TXpress 18,000 -- 18,000 Other 20,000 -- $ 17,000 37,000 Total Device Segment 1,379,000 409,000 17,000 1,805,000 Clinical Development Segment: Manual Disposables 22,000 -- -- 22,000 Bone Marrow -- 23,000 -- 23,000 Other -- 17,000 -- 17,000 Total Clinical Development 22,000 40,000 -- 62,000 Total $ 1,401,000 $ 449,000 $ 17,000 $ 1,867,000 Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not three March 31, 2019 $383,000. $764,000 $485,000 March 31, 2019 December 31, 2018, $300,000 $303,000 March 31, 2019 December 31, 2018, Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Remainder of 2019 2020 2021 2022 2023 and beyond Total Service Revenue $ 1,047,000 $ 683,000 $ 413,000 $ 75,000 -- $ 2,218,000 Clinical Revenue 10,000 14,000 14,000 14,000 $ 198,000 250,000 Total $ 1,057,000 $ 697,000 $ 427,000 $ 89,000 $ 198,000 $ 2,468,000 Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Level 2: Level 3: The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level 3 3
Segment Reporting, Policy [Policy Text Block]	Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (CODM), or decision-making group, whose function is to allocate resources to and assess the performance of the operating segments. The Company has identified its chief executive officer as the CODM. In determining its reportable segments, the Company considered the markets and the products or services provided to those markets. The Company has two ● The Clinical Development Segment, is developing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets. ● The Device Segment, engages in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The device division is operated through the Company’s ThermoGenesis subsidiary.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus the pre-funded warrants. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration and have no 2,465,000 March 31, 2019 March 31: 2019 2018 Common stock equivalents of convertible promissory note and accrued interest 50,967,211 -- Vested Series A warrants 404,412 404,412 Unvested Series A warrants (1) 698,529 698,529 Warrants – other 15,578,847 4,030,600 Stock options 2,909,338 1,206,410 Restricted stock units -- 416 Total 70,558,337 6,340,367 ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021.
Reclassification, Policy [Policy Text Block]	Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended March 31, 2019 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 1,267,000 $ 55,000 $ 1,322,000 BioArchive 599,000 415,000 1,014,000 CAR-TXpress 307,000 -- 307,000 Manual Disposables 294,000 -- 294,000 Other -- -- $ 14,000 14,000 Total Device Segment 2,467,000 470,000 14,000 2,951,000 Clinical Development Segment: Manual Disposables 6,000 -- -- 6,000 Other 5,000 -- -- 5,000 Total Clinical Development 11,000 -- -- 11,000 Total $ 2,478,000 $ 470,000 $ 14,000 $ 2,962,000 Three Months Ended March 31, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 685,000 $ 65,000 $ 750,000 BioArchive 423,000 344,000 767,000 Manual Disposables 233,000 -- 233,000 CAR-TXpress 18,000 -- 18,000 Other 20,000 -- $ 17,000 37,000 Total Device Segment 1,379,000 409,000 17,000 1,805,000 Clinical Development Segment: Manual Disposables 22,000 -- -- 22,000 Bone Marrow -- 23,000 -- 23,000 Other -- 17,000 -- 17,000 Total Clinical Development 22,000 40,000 -- 62,000 Total $ 1,401,000 $ 449,000 $ 17,000 $ 1,867,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]	Remainder of 2019 2020 2021 2022 2023 and Beyond Total Service Revenue $ 1,047,000 $ 683,000 $ 413,000 $ 75,000 -- $ 2,218,000 Clinical Revenue 10,000 14,000 14,000 14,000 $ 198,000 250,000 Total $ 1,057,000 $ 697,000 $ 427,000 $ 89,000 $ 198,000 $ 2,468,000
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	2019 2018 Common stock equivalents of convertible promissory note and accrued interest 50,967,211 -- Vested Series A warrants 404,412 404,412 Unvested Series A warrants (1) 698,529 698,529 Warrants – other 15,578,847 4,030,600 Stock options 2,909,338 1,206,410 Restricted stock units -- 416 Total 70,558,337 6,340,367

Note 5 - Leases (Tables)

Note 5 - Leases (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Lease, Cost [Table Text Block]	March 31, 2019 Right-of-use operating lease assets, net $941,000 Current lease liability 94,000 Non-current lease liability 854,000 March 31, 2019 Weighted average remaining lease term 5.2 Discount rate 22%
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2019 (remaining) $ 220,000 2020 301,000 2021 310,000 2022 319,000 2023 329,000 2024 138,000 Total lease payments $ 1,617,000 Less: imputed interest (669,000 ) Present value of operating lease liabilities $ 948,000

Note 6 - Commitments and Cont_2

Note 6 - Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Product Warranty Liability [Table Text Block]	Balance at December 31, 2018 $ 186,000 Warranties issued during the period 43,000 Settlements made during the period (107,000 ) Changes in liability for pre-existing warranties during the period (39,000 ) Balance at March 31, 2019 $ 83,000

Note 7 - Derivative Obligatio_2

Note 7 - Derivative Obligations (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Series A March 31, 2019 December 31, 2018 Market price of common stock $0.29 $0.27 Expected volatility 96% 94% Contractual term (years) 1.9 2.2 Discount rate 2.28% 2.48% Dividend rate 0% 0% Exercise price $8.00 $8.00
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	Derivative Obligation March 31, 2019 December 31, 2018 Balance $1,000 $1,000 Level 1 $- $- Level 2 $- $- Level 3 $1,000 $1,000
Derivative Instruments, Gain (Loss) [Table Text Block]	Amount Balance – December 31, 2018 $ 1,000 Change in fair value of derivative obligation -- Balance – March 31, 2019 $ 1,000

Note 8 - Stockholders' Equity (

Note 8 - Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2018 3,023,639 $ 1.40 Forfeited (114,301 ) $ 1.11 Outstanding at March 31, 2019 2,909,338 $ 1.41 9 -- Vested and expected to vest at March 31, 2019 1,911,105 $ 1.73 8.8 -- Exercisable at March 31, 2019 876,955 $ 2.79 7.9 --
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Weighted-Average Exercise Price Per Share Balance at December 31, 2018 17,265,208 $ 2.99 Warrants expired (83,420 ) $ 56.20 Warrants exercised (500,000 ) $ 0.01 Outstanding at March 31, 2019 16,681,788 $ 2.81 Exercisable at March 31, 2019 15,983,259 $ 2.58

Note 9 - Segment Reporting (Tab

Note 9 - Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Reconciliation of Revenue from Segments to Consolidated [Table Text Block]	Three Months Ended March 31, 2019 Clinical Development Device Total Net revenues $ 11,000 $ 2,951,000 $ 2,962,000 Cost of revenues 43,000 1,661,000 1,704,000 Gross profit (32,000 ) 1,290,000 1,258,000 Operating expenses 471,000 1,693,000 2,164,000 Operating loss $ (503,000 ) $ (403,000 ) $ (906,000 ) Depreciation and amortization $ 95,000 $ 117,000 $ 212,000 Stock-based compensation expense $ 54,000 $ 27,000 $ 81,000 Goodwill -- $ 781,000 $ 781,000 Total assets $ 4,281,000 $ 11,349,000 $ 15,630,000 Three Months Ended March 31, 2018 Clinical Development Device Total Net revenues $ 62,000 $ 1,805,000 $ 1,867,000 Cost of revenues 71,000 1,444,000 1,515,000 Gross profit (9,000 ) 361,000 352,000 Operating expenses 1,179,000 2,429,000 3,608,000 Operating loss $ (1,188,000 ) $ (2,068,000 ) $ (3,256,000 ) Depreciation and amortization $ 68,000 $ 91,000 $ 159,000 Stock-based compensation expense $ 98,000 $ 39,000 $ 137,000 Goodwill $ 13,195,000 $ 781,000 $ 13,976,000 Total assets $ 38,941,000 $ 11,240,000 $ 50,181,000

Note 1 - Description of Busin_2

Note 1 - Description of Business and Basis of Presentation (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance	$ 956,000		$ (1,711,000)
Reorganization of Subsidiary and Related Change in Non-controlling Interest
Cash and Cash Equivalents, at Carrying Value, Ending Balance	2,237,000		2,400,000
Working Capital	3,246,000
Retained Earnings (Accumulated Deficit), Ending Balance	(229,306,000)		$ (227,435,000)
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Long-term Line of Credit, Total	8,713,000
Line of Credit Facility, Maximum Borrowing Capacity	10,000,000
Noncontrolling Interest [Member]
Reorganization of Subsidiary and Related Change in Non-controlling Interest	2,843,000
ThermoGenesis [Member]
Ownership in Subsidiary Exchanged		20.00%
Noncontrolling Interest, Ownership Percentage by Parent		100.00%
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance	(1,711,000)
CAR-TXpress [Member]
Minority Interest Acquired Through Exchange		20.00%
Noncontrolling Interest, Ownership Percentage by Parent		80.00%
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance	$ 1,100,000

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)	3 Months Ended
	Mar. 31, 2019USD ($)shares	Mar. 31, 2018shares	Jan. 01, 2019USD ($)	Dec. 31, 2018USD ($)
Operating Lease, Right-of-Use Asset	$ 941,000
Operating Lease, Liability, Total	948,000
Contract with Customer, Liability, Revenue Recognized	383,000
Contract with Customer, Liability, Current	764,000			485,000
Contract with Customer, Liability, Noncurrent	$ 300,000			$ 303,000
Number of Reportable Segments	2
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares	70,558,337	6,340,367
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares	2,465,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset			$ 966,000
Operating Lease, Liability, Total			$ 966,000

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Revenues (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Net revenues	$ 2,962,000	$ 1,867,000
Device [Member]
Net revenues	2,951,000	1,805,000
Device [Member] | AXP [Member]
Net revenues	1,322,000	750,000
Device [Member] | BioArchive [Member]
Net revenues	1,014,000	767,000
Device [Member] | CAR-TXpress [Member]
Net revenues	307,000	18,000
Device [Member] | Manual Disposables [Member]
Net revenues	294,000	233,000
Device [Member] | Other Subsegments [Member]
Net revenues	14,000	37,000
Clinical Development [Member]
Net revenues	11,000	62,000
Clinical Development [Member] | Manual Disposables [Member]
Net revenues	6,000	22,000
Clinical Development [Member] | Other Subsegments [Member]
Net revenues	5,000	17,000
Clinical Development [Member] | Bone Marrow [Member]
Net revenues		23,000
Device Revenue [Member]
Net revenues	2,478,000	1,401,000
Device Revenue [Member] | Device [Member]
Net revenues	2,467,000	1,379,000
Device Revenue [Member] | Device [Member] | AXP [Member]
Net revenues	1,267,000	685,000
Device Revenue [Member] | Device [Member] | BioArchive [Member]
Net revenues	599,000	423,000
Device Revenue [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	307,000	18,000
Device Revenue [Member] | Device [Member] | Manual Disposables [Member]
Net revenues	294,000	233,000
Device Revenue [Member] | Device [Member] | Other Subsegments [Member]
Net revenues		20,000
Device Revenue [Member] | Clinical Development [Member]
Net revenues	11,000	22,000
Device Revenue [Member] | Clinical Development [Member] | Manual Disposables [Member]
Net revenues	6,000	22,000
Device Revenue [Member] | Clinical Development [Member] | Other Subsegments [Member]
Net revenues	5,000
Device Revenue [Member] | Clinical Development [Member] | Bone Marrow [Member]
Net revenues
Service [Member]
Net revenues	470,000	449,000
Service [Member] | Device [Member]
Net revenues	470,000	409,000
Service [Member] | Device [Member] | AXP [Member]
Net revenues	55,000	65,000
Service [Member] | Device [Member] | BioArchive [Member]
Net revenues	415,000	344,000
Service [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues
Service [Member] | Device [Member] | Manual Disposables [Member]
Net revenues
Service [Member] | Device [Member] | Other Subsegments [Member]
Net revenues
Service [Member] | Clinical Development [Member]
Net revenues		40,000
Service [Member] | Clinical Development [Member] | Manual Disposables [Member]
Net revenues
Service [Member] | Clinical Development [Member] | Other Subsegments [Member]
Net revenues		17,000
Service [Member] | Clinical Development [Member] | Bone Marrow [Member]
Net revenues		23,000
Other [Member]
Net revenues	14,000	17,000
Other [Member] | Device [Member]
Net revenues	14,000	17,000
Other [Member] | Device [Member] | AXP [Member]
Net revenues
Other [Member] | Device [Member] | BioArchive [Member]
Net revenues
Other [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues
Other [Member] | Device [Member] | Manual Disposables [Member]
Net revenues
Other [Member] | Device [Member] | Other Subsegments [Member]
Net revenues	14,000	17,000
Other [Member] | Clinical Development [Member]
Net revenues
Other [Member] | Clinical Development [Member] | Manual Disposables [Member]
Net revenues
Other [Member] | Clinical Development [Member] | Other Subsegments [Member]
Net revenues
Other [Member] | Clinical Development [Member] | Bone Marrow [Member]
Net revenues

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations (Details)	Mar. 31, 2019USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 2,468,000
Service [Member]
Revenue, Remaining Performance Obligation, Amount	2,218,000
Clinical Revenue [Member]
Revenue, Remaining Performance Obligation, Amount	$ 250,000

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations 2 (Details)	Mar. 31, 2019USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 2,468,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 1,057,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 697,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 427,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 89,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 198,000
Service [Member]
Revenue, Remaining Performance Obligation, Amount	$ 2,218,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 1,047,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 683,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 413,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 75,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount
Clinical Revenue [Member]
Revenue, Remaining Performance Obligation, Amount	$ 250,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 10,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 14,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 14,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 14,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 198,000

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares		3 Months Ended
		Mar. 31, 2019	Mar. 31, 2018
Anti-dilutive securities (in shares)		70,558,337	6,340,367
Convertible Debt Securities [Member]
Anti-dilutive securities (in shares)		50,967,211
Vested Series A Warrants [Member]
Anti-dilutive securities (in shares)		404,412	404,412
Unvested Series A Warrants [Member]
Anti-dilutive securities (in shares)	[1]	698,529	698,529
Warrant, Other [Member]
Anti-dilutive securities (in shares)		15,578,847	4,030,600
Share-based Payment Arrangement, Option [Member]
Anti-dilutive securities (in shares)		2,909,338	1,206,410
Restricted Stock Units (RSUs) [Member]
Anti-dilutive securities (in shares)			416
[1]	The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants will remain outstanding but unvested until they expire in February 2021.

Note 3 - Related Party Transa_2

Note 3 - Related Party Transactions (Details Textual) - USD ($)	Mar. 12, 2018	Aug. 21, 2017	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Apr. 16, 2018	Apr. 01, 2018
Amortization of Debt Discount (Premium)			$ 586,000
Interest Expense, Total			1,132,000	361,000
Adjustments for New Accounting Principle, Early Adoption [Member] | Accounting Standards Update 2017-11 [Member]
Debt Instrument, Unamortized Discount, Total			1,513,000				$ 7,200,000
Amortization of Debt Discount (Premium)			586,000
Boyalife Investment Fund II, Inc. [Member] | Convertible Debt [Member]
Debt Instrument, Convertible, Conversion Price					$ 0.18	$ 1.61
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity			10,000,000
Proceeds from Long-term Lines of Credit			8,713,000		$ 7,200,000
Line of Credit Facility, Remaining Borrowing Capacity			$ 1,287,000
Debt Instrument, Interest Rate, Stated Percentage			22.00%
Interest Expense, Total			$ 1,047,000	360,000
Interest Payable			461,000		$ 1,513,000
Boyalife W.S.N. [Member]
Distributor Agreement Term		3 years
Distributor Agreement, Renewal Term		2 years
Revenue from Related Parties			$ 266,000	$ 226,000
IncoCell [Member]
Contract Development Revenue, Term	10 years

Note 4 - Note Payable (Details

Note 4 - Note Payable (Details Textual) - USD ($)	Jan. 29, 2019	Mar. 31, 2019	Dec. 31, 2018
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001	$ 0.001
Convertible Debt [Member] | Notes [Member]
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	90.00%
Debt Instrument, Interest Rate, Stated Percentage	24.00%
Debt Instrument, Term	1 year 180 days
Debt Instrument, Convertible, First Customary Conversion Blockers	4.99%
Debt Instrument, Convertible, Second customary conversion blockers	9.99%
Convertible Debt [Member] | Notes [Member] | Maximum [Member]
Debt Instrument, Face Amount	$ 800,000
Debt Instrument, Convertible, Conversion Price	$ 0.18
Convertible Debt [Member] | Notes [Member] | Minimum [Member]
Debt Instrument, Convertible, Conversion Price	$ 0.05

Note 5 - Leases (Details Textua

Note 5 - Leases (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Operating Lease, Weighted Average Remaining Lease Term	5 years 73 days
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	$ 966,000
Operating Lease, Payments	71,000
Operating Lease, Cost	$ 103,000

Note 5 - Leases - Lease Informa

Note 5 - Leases - Lease Information (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Right-of-use operating lease assets, net	$ 941,000
Current lease liability	94,000
Non-current lease liability	$ 854,000
Weighted average remaining lease term (Year)	5 years 73 days
Discount rate	22.00%

Note 5 - Leases - Maturities of

Note 5 - Leases - Maturities of Lease Liabilities (Details)	Mar. 31, 2019USD ($)
2019 (remaining)	$ 220,000
2020	301,000
2021	310,000
2022	319,000
2023	329,000
2024	138,000
Total lease payments	1,617,000
Less: imputed interest	(669,000)
Present value of operating lease liabilities	$ 948,000

Note 6 - Commitments and Cont_3

Note 6 - Commitments and Contingencies (Details Textual) - USD ($)	May 04, 2017	Oct. 31, 2017	Mar. 31, 2019
Payment Terms, Severance Compensation			1 year
Short Term Investment Minimum			$ 2,000,000
Litigation Related to Strategic Advisory Services [Member]
Loss Contingency, Damages Sought, Value	$ 1,000,000
Loss Contingency, Damages Sought, Value, Interest			300,000
Loss Contingency, Negotiation Condition Bond		$ 1,000,000
Loss Contingency Accrual, Ending Balance			$ 0

Note 6 - Commitments and Cont_4

Note 6 - Commitments and Contingencies - Changes in Product Liability Included in Accrued Liabilities (Details)	3 Months Ended
	Mar. 31, 2019USD ($)
Balance	$ 186,000
Warranties issued during the period	43,000
Settlements made during the period	(107,000)
Changes in liability for pre-existing warranties during the period	(39,000)
Balance	$ 83,000

Note 7 - Derivative Obligatio_3

Note 7 - Derivative Obligations (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Jun. 30, 2016
Class of Warrant or Right, Outstanding	16,681,788		17,265,208
Derivative, Gain (Loss) on Derivative, Net, Total	$ 0	$ 259,000
Series A Warrant [Member]
Class of Warrant or Right, Outstanding				404,412

Note 7 - Derivative Obligatio_4

Note 7 - Derivative Obligations - Fair Value Assumptions (Details) - Series A Warrant [Member]	Mar. 31, 2019	Dec. 31, 2018
Measurement Input, Share Price [Member]
Valuation assumption	0.29	0.27
Measurement Input, Price Volatility [Member]
Valuation assumption	0.96	0.94
Measurement Input, Expected Term [Member]
Valuation assumption	1.9	2.2
Measurement Input, Discount Rate [Member]
Valuation assumption	0.0228	0.0248
Measurement Input, Expected Dividend Rate [Member]
Valuation assumption	0	0
Measurement Input, Exercise Price [Member]
Valuation assumption	8	8

Note 7 - Derivative Obligatio_5

Note 7 - Derivative Obligations - Fair Value Hierarchy (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Derivative obligations	$ 1,000	$ 1,000
Fair Value, Inputs, Level 1 [Member]
Derivative obligations
Fair Value, Inputs, Level 2 [Member]
Derivative obligations
Fair Value, Inputs, Level 3 [Member]
Derivative obligations	$ 1,000	$ 1,000

Note 7 - Derivative Obligatio_6

Note 7 - Derivative Obligations - Change in Fair Value of Derivative Liabilities (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Balance	$ 1,000
Change in fair value of derivative obligation	0	$ (259,000)
Balance	$ 1,000

Note 8 - Stockholders' Equity_2

Note 8 - Stockholders' Equity (Details Textual) - USD ($)	Mar. 28, 2018	Mar. 31, 2019	Mar. 31, 2018
Stock Issued During Period, Shares, New Issues	609,636
Shares Issued, Price Per Share	$ 2.27
Payments of Stock Issuance Costs	$ 171,000
Proceeds from Issuance of Common Stock, Net	$ 1,213,000		$ 1,213,000
Share-based Payment Arrangement, Expense		$ 81,000	$ 137,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		0
Warrants Issused in Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	304,818
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.68
Warrants and Rights Outstanding, Term	5 years 182 days

Note 8 - Stockholders' Equity -

Note 8 - Stockholders' Equity - Option Activity for Stock Option Plans (Details)	3 Months Ended
	Mar. 31, 2019USD ($)$ / sharesshares
Outstanding, options (in shares) | shares	3,023,639
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 1.40
Forfeited, options (in shares) | shares	(114,301)
Forfeited, weighted average exercise price, options (in dollars per share) | $ / shares	$ 1.11
Outstanding, options (in shares) | shares	2,909,338
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 1.41
Outstanding, weighted average remaining contractual life, options (Year)	9 years
Outstanding, aggregate intrinsic value, options | $
Vested and Expected to Vest, options (in shares) | shares	1,911,105
Vested and Expected to Vest, weighted average exercise price, options (in dollars per share) | $ / shares	$ 1.73
Vested and Expected to Vest, weighted average remaining contractual life, options (Year)	8 years 292 days
Vested and Expected to Vest, aggregate intrinsic value, options | $
Exercisable, options (in shares) | shares	876,955
Exercisable, weighted average exercise price, options (in dollars per share) | $ / shares	$ 2.79
Exercisable, weighted average remaining contractual life, options (Year)	7 years 328 days
Exercisable, aggregate intrinsic value, options | $

Note 8 - Stockholders' Equity_3

Note 8 - Stockholders' Equity - Warrant Activity (Details)	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Outstanding (in shares) | shares	17,265,208
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 2.99
Warrants expired (in shares) | shares	(83,420)
Warrants expired (in dollars per share) | $ / shares	$ 56.20
Warrants exercised (in shares) | shares	(500,000)
Warrants exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 0.01
Outstanding (in shares) | shares	16,681,788
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 2.81
Exercisable (in shares) | shares	15,983,259
Exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 2.58

Note 9 - Segment Reporting (Det

Note 9 - Segment Reporting (Details Textual)	3 Months Ended
	Mar. 31, 2019
Number of Reportable Segments	2

Note 9 - Segment Reporting - Su

Note 9 - Segment Reporting - Summary of Operating Results by Reportable Segments (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Net revenues	$ 2,962,000	$ 1,867,000
Cost of revenues	1,704,000	1,515,000
Gross profit	1,258,000	352,000
Operating expenses	2,164,000	3,608,000
Operating loss	(906,000)	(3,256,000)
Depreciation and amortization	212,000	159,000
Stock-based compensation expense	81,000	137,000
Goodwill	781,000	13,976,000	$ 781,000
Total assets	15,630,000	50,181,000	14,611,000
Goodwill	781,000	13,976,000	781,000
Total assets	15,630,000	50,181,000	$ 14,611,000
Clinical Development [Member]
Net revenues	11,000	62,000
Clinical Development [Member] | Operating Segments [Member]
Net revenues	11,000	62,000
Cost of revenues	43,000	71,000
Gross profit	(32,000)	(9,000)
Operating expenses	471,000	1,179,000
Operating loss	(503,000)	(1,188,000)
Depreciation and amortization	95,000	68,000
Stock-based compensation expense	54,000	98,000
Goodwill		13,195,000
Total assets	4,281,000	38,941,000
Goodwill		13,195,000
Total assets	4,281,000	38,941,000
Device [Member]
Net revenues	2,951,000	1,805,000
Device [Member] | Operating Segments [Member]
Net revenues	2,951,000	1,805,000
Cost of revenues	1,661,000	1,444,000
Gross profit	1,290,000	361,000
Operating expenses	1,693,000	2,429,000
Operating loss	(403,000)	(2,068,000)
Depreciation and amortization	117,000	91,000
Stock-based compensation expense	27,000	39,000
Goodwill	781,000	781,000
Total assets	11,349,000	11,240,000
Goodwill	781,000	781,000
Total assets	$ 11,349,000	$ 11,240,000

Note 10 - Subsequent Events (De

Note 10 - Subsequent Events (Details Textual) - USD ($)	Apr. 18, 2019	Apr. 30, 2019	Mar. 31, 2019
Class of Warrant or Right, Exercised During Period			500,000
Subsequent Event [Member] | April 2019 Pre-funded Warrants [Member]
Class of Warrant or Right, Issued During Period	4,444,444
Warrants Issued, Price Per Warrant	$ 0.17
Proceeds from Issuance of Warrants	$ 755,555
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	1
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.01
Subsequent Event [Member] | August 2018 Pre-funded Warrants [Member]
Proceeds from Issuance of Warrants		$ 15,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.01
Class of Warrant or Right, Exercised During Period		1,500,000